Myeloperoxidase
Myeloperoxidase (MPO) is an inflammation-associated heme enzyme involved in oxidative processes.
Myeloperoxidase (MPO) is an inflammation-associated heme enzyme involved in oxidative processes. It is particularly relevant to neutrophil biology and has been linked to cardiovascular oxidative stress, inflammatory mechanisms, and cancer progression. Because MPO activity can be measured in biological samples, the enzyme is studied both as a mechanistic mediator and as a potential biomarker of inflammatory activity.
MPO is also being investigated as a pharmacological target. Recent work has examined selective MPO inhibition, including the clinical-development candidate mitiperstat, as well as activity-based analytical methods for detecting MPO in complex samples. Its disease relevance has been explored alongside reactive oxygen species, oxidative stress, proinflammatory cytokines such as interleukin-1β (IL-1β), interleukin-6 (IL-6), interleukin-17A (IL-17A), and tumor necrosis factor-α (TNF-α), and inflammatory mediators including matrix metallopeptidase 8 and nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB).
Rebuilt from PubMed 18 Sept 2026 · no new papers today
Where the papers sit
12 papers study myeloperoxidase directly. The themes below are drawn from those 12. 1 new direction follows.
-
Myeloperoxidase Clinical Translation : Myeloperoxidase work ranges from inhibitor discovery and mitiperstat pharmacokinetics to vascular, periodontal and joint biomarkers, alongside granulocyte immunotherapy. No single clinical direction unifies these studies. 6 papers · 50%
-
Catalytic ROS Therapy and Detection : pH-activated Fe nanozymes are being applied to eradicate resistant H. pylori and enhance doxorubicin therapy, while CRISPR nanowires improve MPO activity detection. ROS generation and trans-cleavage recur. 3 papers · 25%
-
MPO in Kidney Disease : MPO-ANCA testing and MPO/NE expression are being linked to glomerulonephritis and diabetic kidney injury, with albuminuria and creatinine recurring endpoints. The focus is risk stratification and earlier diagnosis rather than unified treatment. 3 papers · 25%
Myeloperoxidase is a regulator of granulocyte-monocyte progenitor expansion and an enabler of engineered cellular immunotherapy
The expansion and CAR engineering of mouse and human granulocyte-monocyte progenitors found that myeloperoxidase regulates GMP proliferation, rather than serving only as an inflammatory enzyme, disease-associated biomarker, therapeutic target, or activity-detection analyte. This gives MPO a previously unrepresented role in maintaining an expandable, engineerable progenitor platform whose derivatives restore antibacterial defense and generate antitumor macrophage and CAR-mediated immunity, redirecting attention toward MPO-dependent control of hematopoietic cell production and immunotherapy manufacture 42320470Jun.
Recent Findings on Myeloperoxidase
Inflammation and MPO Therapeutics: Elevated MPO tracks inflammatory burden in intracranial atherosclerosis and periodontitis, while synovial MPO falls after regenerative injections. 42622237Aug41910651Mar42472796Jul Pharmacophore modeling, QSAR, molecular dynamics, and biological testing identified BTB11556 as a lead MPO inhibitor with cytotoxic activity against Kasumi-1 leukemia cells. 42572067Aug Mitiperstat development is advancing through population pharmacokinetics, with severe renal impairment and lower body weight producing the largest exposure increases. 42101107May MPO also regulates granulocyte-monocyte progenitor proliferation, enabling CAR-engineered progenitors to generate tumor-infiltrating macrophages and suppress CD19-positive leukemia and HER2-positive solid tumors. 42320470Jun Associations were not uniform: continuous granulocyte colony-stimulating factor lacked significant relationships with atherosclerosis, and hypertonic dextrose and concentrated growth factors produced similar MPO reductions. 42622237Aug42472796Jul
Peroxidase-Based Nanotechnology: Fe3O4-based nanozymes and Fe-doped carbon dots use peroxidase-like catalysis, acidic activation, and reactive oxygen species generation for targeted treatment. 42208681May42008939Apr Casein-coated Fe3O4 nanozymes increased peroxidase-like activity by 91%, carried substantial doxorubicin, and enhanced cytotoxicity against MCF-7 cells through Fenton-reaction ROS production. 42208681May Fe-CDs combined oxidase- and peroxidase-like activities with ammonium-mediated H. pylori binding and Urel targeting, reducing antibiotic-resistant H. pylori in infected mice while preserving commensal microbiota. 42008939Apr A DNA nanowire-assisted CRISPR/Cas12a triple cascade detected MPO activity at 10.20 pg/mL and showed different signal distributions in acute coronary syndrome and healthy serum samples. 42503780Jul The assay’s serum signals remain potentially affected by eosinophil peroxidase/HOBr-mediated probe activation, whereas the nanozyme studies emphasize therapeutic efficacy and negligible toxicity. 42503780Jul42008939Apr
MPO in Kidney Disease: Peripheral blood leukocyte MPO and neutrophil elastase mRNA increase selectively in A3 diabetic kidney disease and correlate independently with albuminuria. 42742850Sep ANCA testing in secondary care identifies many positive results without ANCA-associated vasculitis, while ELISA-first strategies provide higher specificity and positive predictive value than indirect immunofluorescence-first testing. 42715168Sep A pediatric renal-limited case shows that school urinary screening can detect MPO-ANCA-associated glomerulonephritis with preserved renal function, and methylprednisolone, rituximab, and azathioprine normalized MPO-ANCA levels and proteinuria. 42371244Jun Together, these findings link MPO-related measurements to albuminuria, diagnostic refinement, and early recognition, while larger longitudinal studies remain needed to validate MPO and neutrophil elastase as markers of severe diabetic kidney disease. 42742850Sep
Written from 12 PubMed abstracts, each one cited by PMID above. Published: 2026-09-02. Last written: 2026-09-17 by GPT. Drafted by language models from published abstracts; not medical advice.